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Abstract
Background: Mucormycosis is a rare but devastating fungal infection primarily affecting immunocompromised
patients such as those with hematological malignancy, bone marrow and solid organ transplantation, and patients
with diabetes, and, even more rarely, immunocompetent patients. The objective of this study was to assess the
prevalence and burden, both clinical and economic, of mucormycosis among hospitalized patients in the U.S.
Methods: This is a retrospective study using the Premier PerspectiveTM Comparative Database, with more than 560
participating hospitals covering 104 million patients (January 2005-June 2014). All hospitalizations in the database
were evaluated for the presence of mucormycosis using either an ICD-9 code of 117.7 or a positive laboratory result
for Mucorales. Hospitalizations were further required to have prescriptions of amphotericin B or posaconazole to be
considered as mucormycosis-related hospitalizations. The prevalence of mucormycosis-related hospitalizations
among all hospital discharges was estimated. Mortality rate at discharge, length of hospital stay, and readmission
rates at 1 and 3 months were evaluated among mucormycosis-related hospitalizations. Cost per hospital stay and
average per diem cost (inflated to 2014 USD) were reported.
Results: The prevalence of mucormycosis-related hospitalizations was estimated as 0.12 per 10,000 discharges
during January 2005-June 2014. It increased to 0.16 per 10,000 discharges if the definition of mucormycosis was
relaxed to not require the use of amphotericin B or posaconazole. The median length of stay was 17 days, with
23% dead at discharge; readmission rates were high, with 30 and 37% of patients readmitted within one and
three months of discharge, respectively. The average cost per hospital stay was $112,419, and the average per diem
cost was $4,096.
Conclusions: The study provides a recent estimate of the prevalence and burden of mucormycosis among
hospitalized patients. The high clinical and economic burden associated with mucormycosis highlights the
importance of establishing active surveillance and optimizing prophylactic and active treatment in susceptible
patients.
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Background
Mucormycosis (formerly known as zygomycosis) is an un-
common, opportunistic fungal infection primarily caused
by Mucorales, a filamentous fungus of the Mucormycetes
class. This particular fungal infection typically shows a
rapid progression and primarily affects patients with dia-
betes mellitus or compromised immune systems, such as
those with hematologic malignancies, stem cell and solid
organ transplants [1, 2]. Information on the prevalence of
this disease is limited as there is no systematic reporting
and non-specialized physicians can misdiagnose it in clin-
ical practice. One study that used population-based active
laboratory surveillance estimated that there were 1.7
mucormycosis cases per million individuals per year in the
San Francisco Bay Area between 1992 and 1993 [3]. A
more recent study in the U.S. reported an annual inci-
dence rate of 0.07 and 0.29% in patients undergoing solid
organ transplants and hematopoietic cell transplants, re-
spectively, during 2001-2006 [4]. In addition, an analysis
of U.S. hospital discharge data from the Healthcare Cost
and Utilization Project – Nationwide Inpatient Sample
(HCUP-NIS) reported 5,515 mucormycosis cases among
146 million hospitalizations of high-risk patients, i.e., im-
munocompromised, critically ill patients and patients with
major surgery or pneumonia during 2003-2010. The num-
ber of mucormycosis cases was extrapolated to ~5,800 if
all the ~ 300 million hospitalizations in the database were
included for evaluation (~0.19 cases per 10,000 dis-
charges) [5]. With the improvement in the care of critic-
ally ill and immunocompromised patients in the past few
years, the prevalence of invasive fungal infections, includ-
ing mucormycosis, might have changed [1, 3, 6, 7].
Amphotericin B (especially its lipid formulation), posa-
conazole and the recently approved triazole, isavucona-
zole, in conjunction with surgery, are the only active
agents against mucormycosis, and are recommended by
treatment guidelines [8–13]. Even with treatment, how-
ever, mucormycosis is associated with a high mortality
rate [14]. Based on two systematic reviews, survival
among patients treated with antifungal therapy and/or
surgery ranged from 52.2 to 70% [15, 16]. A study using
data from 2003-2010, reported an in-hospital mortality
rate of 22% among inpatient mucormycosis cases [5].
In addition to the high mortality rate, mucormycosis is
also associated with long hospital stays and substantial
costs. Based on a study published in 2012, the average
direct cost per episode of mucormycosis was estimated
to be $113,511 (2004 USD), which was higher than
more common invasive infections such as aspergillosis
($65,001; 2004 USD) and candidiasis ($81,271; 2004
USD) [17].
To provide an up-to-date overview on the epidemi-
ology and burden of mucormycosis in the general
population of hospitalized patients in U.S., we sought to
estimate the prevalence of mucormycosis and to assess
the clinical and economic burden associated with




The study used the Premier’s Perspective™ Comparative
Database (Premier), spanning from January 2005 to June
2014. Premier is a large, U.S. hospital-based database
covering more than 560 participating hospitals and 104
million patients. Participating hospitals represent all re-
gions of the U.S., are mainly non-teaching facilities, and
mostly serve urban patient population. Information col-
lected includes patient demographics (age, gender, and
race/ethnicity), principal and secondary diagnoses, prin-
cipal and secondary procedures, length of stay, drug
utilization (drug name and strength, quantity dispensed,
and unit cost), and cost of care. Laboratory results are
available from the SafetySurveillor™ product from 2009
and on for about 37% of the hospitals.
Sample selection for mucormycosis-related
hospitalizations
Mucormycosis-related hospitalizations were identified as
hospitalizations with an International Classification of
Diseases 9th Edition (ICD-9) code of 117.7 (either pri-
mary or secondary) or a positive laboratory microbiology
result for Mucorales, the organisms that cause mucor-
mycosis [10]. To decrease the chance of false positive re-
sults, we further required all eligible encounters to have
at least one prescription of amphotericin B or posacona-
zole to be qualified as mucormycosis-related hospitaliza-
tions. Amphotericin B and posaconazole were selected
because they are the only treatments with efficacy in
treating mucormycosis [8, 9, 18–21].
Prevalence estimation
Prevalence of mucormycosis was estimated annually by
dividing the number of mucormycosis-related hospitali-
zations by the total number of all hospital discharges
observed in the same year. An alternative calculation of
the prevalence was conducted by relaxing the definition
of mucormycosis-related hospitalizations to require only
the ICD-9 code or a positive laboratory microbiology
test, without the antifungal drug use restriction.
Analysis of clinical and economic burden
Characteristics of hospitals and patients with
mucormycosis-related hospitalizations were summa-
rized. Hospital characteristics included region, bed size,
teaching facilities, and urban/rural setting. Patient char-
acteristics included age, gender, race, and underlying
conditions, and were summarized based on disease
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history present in the data within 12 months preceding
the admission with mucormycosis.
The clinical and economic outcomes assessed included
death at discharge, length of stay, and readmission rates at
1 and 3 months. Death at discharge was identified using
discharge status ‘expired’. The cost for hospitalization in-
cluded all supplies, labor, depreciation of equipment, etc.
All costs were inflated to 2014 USD using the medical
care component of the Consumer Price Index. Continu-
ous variables were summarized by mean, standard devi-
ation, median, and range; proportions were reported for




A total of 555 mucormycosis-related hospitalizations were
identified among 47,131,360 total inpatient encounters in
the Premier data during January 2005 to June 2014.
(Additional file 1: Figure S1) The estimated prevalence
was 0.12 (range 0.09, 0.17) per 10,000 discharges during
the study period. There was no clear trend of changes in
prevalence across the years. In the sensitivity analysis, the
estimated prevalence increased to 0.16 (range 0.12, 0.20)
per 10,000 discharges (Fig. 1) after the removal of antifun-
gal drug use restriction.
Hospital and patient characteristics
The identified mucormycosis-related hospitalizations were
from 177 distinct hospitals. Most of these hospitals were
large (67%) with a bed size > 300, and 42% of the hospitals
were affiliated with teaching facilities. Our sample was
predominantly from urban hospitals, accounting for more
than 90% of the inpatient mucormycosis encounters in-
cluded in this study (Table 1).
The average age of the patients with mucormycosis-
related hospitalizations was 51.7 years. About 29% of
them were aged 65 years or older. 63% of the patients
were males and approximately 61% were white. The
most common underlying condition was diabetes (52%),
followed by hematological malignancies (40%) (Table 1).
Clinical and economic outcomes
The median length of stay for the patients was approxi-
mately 17 days. The range for the length of stay was
relatively wide, extending from 1 to 259 days. A total of
225 (41%) patients were admitted to intensive care units
(ICUs) during the mucormycosis-related hospitaliza-
tions. The death rate at discharge was high, with 23% of
the patients dead at discharge. The rate was somewhat
higher among patients with hematological malignancies
than those with diabetes (23 vs. 19%). Nearly one third

























Prevalence of mucormycosis-related hospitalizations1
Without drug use restriction
(N = 775)
With drug use restriction
(N = 555)
Fig. 1 Prevalence of mucormycosis-related hospitalizations. Note: [1] Mucormycosis encounters with drug restriction were identified using ICD-9 codes
or laboratory results and required at least one use of amphotericin B or posaconazole
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within a month after the discharge, and 37% were re-
admitted within 3 months of the discharge (Table 2).
The most common antifungal drugs used were ampho-
tericin B lipid complex (52%), followed by liposomal
amphotericin B (45%) and posaconazole (45%), which
was consistent with what was observed in the sample
without requiring the use of amphotericin B or posaco-
nazole (N = 775). (Additional file 2: Table S1)
The average cost per hospital stay was $112,419
(standard deviation $159,144) with a range of $1,912
to $1,395,163. The mean per diem cost during
hospitalization was $4,096, with a range of $768 to
$19,728 (Table 2). The mean daily cost for patients
with hematologic malignancies was $4,343 (standard
deviation $2,733) with a range of $1,081 to $19,728),
while it was $3,761 (standard deviation $2,327) with a range
$768 to $16,387 for those with diabetes. The mean daily
cost for patients with and without ICU admission during
the hospitalization was $5,107 (standard deviation $2,995)
and $3,407 (standard deviation $2,200), respectively.
Discussion
The current study utilized recent hospital-based data,
ranging from January 2005 to June 2014, and found that
the prevalence of mucormycosis-related hospitalizations
during this period was 0.12 per 10,000 discharges. The
estimate was lower than what has been reported in the
Table 1 Characteristics of Hospitals and Patients









Bed size range, n (%)





Teaching facility, n (%)
No 102 (58)
Yes 75 (42)
Urban-rural setting, n (%)
Urban 162 (92)
Rural 15 (8)












Age, years, mean (SD) 51.7 (19.6)
Age, years, n (%)
< 18 44 (8)
18–64 351 (63)
≥ 65 160 (29)
Underlying conditions, n (%)
Diabetes 286 (52)
Hematological malignancies 222 (40)
Other invasive fungal infection 92 (17)
Transplant complications 89 (16)
Table 1 Characteristics of Hospitals and Patients (Continued)
Major solid organ transplantation 82 (15)
Stem cell transplantation 63 (11)
Solid tumor 36 (6)
Trauma/burn 20 (4)
HIV/AIDS 10 (2)





Length of stay in days, Median
(range)
17 (1–259)
Deaths at discharge, n (%) 130 (23)
1-month readmission, n (%) 168 (30)
3-month readmission, n (%) 206 (37)
Economic outcomes Cost (2014 USD)
Total cost per hospital stay
Mean (SD) $112,419 ($159,144)
Median (Range) $57,324 ($1,912 - $1,395,163)
Per diem cost
Mean (SD) $4,096 ($2,683)
Median (Range) $3,442 ($768 - $19,728)
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2003-2010 HCUP-NIS study for two possible reasons
[5]. Firstly, the current study utilized more recent data
(January 2005 to June 2014) and therefore reflected the
prevalence of a different time period than the HCUP-
NIS study. More importantly, the current study required
the use of amphotericin B or posaconazole when
identifying mucormycosis-related hospitalizations to re-
duce false positives, which has been previously used and
validated by a number of studies [22]. We noticed that
28% of hospital stays with an ICD-9 code or microbiol-
ogy results of mucormycosis in our study did not have
any prescriptions for amphotericin B or posaconazole.
Hence, using only ICD-9 code to estimate prevalence
may potentially lead to an over-estimate of the preva-
lence. Both the median length of hospital stay observed
and the average cost per hospital stay in our study were
greater than those in the HCUP-NIS study (17 days vs.
14 days and $112,419 vs. $90,107, respectively) [5],
which can also be due to the potential inclusion of false
positives by using only ICD-9 code when identifying
mucormycosis-related hospitalizations.
When the definition for mucormycosis-related hospitali-
zations was relaxed to not require anti-fungal use, the
overall prevalence increased to 0.16 per 10,000 discharges,
which was similar to that reported in the 2003-2010
HCUP-NIS study. This is a 23% increase in prevalence
when compared to 0.13 per 10,000 discharges reported for
the period of 1992-1993 by Rees et al., (which also did not re-
quire anti-fungal drug use when identifying mucormycosis-
related hospitalizations) [3]. There was, however, no clear
trend observed in terms of how the prevalence has chan-
ged between 2005 and 2014 from the present study.
In our study, the economic burden associated with a
mucormycosis-related hospitalization was substantial,
with average cost per stay at $112,419, which was
comparable to the cost of mucormycosis reported in the
literature ($113,511; 2004 USD), and higher than the
average cost reported for both aspergillosis-related hos-
pitalizations and candidiasis-related hospitalizations
($65,001 and $81,271; 2004 USD, respectively), reflecting
the significant morbidity and mortality of mucormycosis
[17]. Specifically, the high cost per mucormycosis-
related hospitalizations could be related to patients’
prolonged hospital stays, heavy use of intensive care
services, and often severe underlying conditions [5]. By
multiplying the prevalence of mucormycosis and the
average cost of mucormycosis-related hospitalizations
observed in this study with the total number of US
hospital discharges in 2013 (35,597,792), we projected
that the total cost associated with mucormycosis could
amount to approximately $48 million per year.
Amphotericin B lipid complex (52%) was the most
commonly used treatment, followed by liposomal
amphotericin B (45%) and posaconazole (45%) among
patients with mucormycosis-related hospitalizations ob-
served in the present study. Although Mucorales have
been shown to be resistant to drugs such as fluconazole
and voriconazole, they were used in 21% and 23% of the
mucormycosis-related hospitalizations. Due to lack of
time stamps of the drug prescriptions, it was not clear if
these fluconazole and voriconazole prescriptions were
intended to treat mucormycosis or were intended to
serve as prophylaxis treatment for patients with high risk
of various invasive fungal infections, such as patients
with leukemia and recipients of stem cell transplantation
[8, 23]. Given the study period (2005 – 2014), data re-
garding the more recently approved drug isavuconazole
were not captured.
Our study has several limitations that should be taken
into consideration when interpreting the results. First, only
a subset of hospitals in Premier submitted laboratory
microbiology results, and laboratory microbiology results
were not available before 2009. In addition, it is possible
that some of the hospitalizations without use of amphoteri-
cin B or posaconazole were true mucormycosis cases, or
that some mucormycosis cases were identified post-
mortem, which might not have been completely captured
by the data [24, 25]. Due to lack of histopathology data,
cases identified by histopathology only and didn’t have posi-
tive microbiology results or the ICD-9 code could have
been missed as well. Such limitations coupled with a high
rate of underdiagnoses for mucormycosis in clinical prac-
tice could have led to an underestimation of the prevalence
of mucormycosis in our study [8, 26]. Second, more than
90% of the encounters included in the final sample were
from urban hospitals, which might not be representative of
U.S. hospitals. Third, clinically important information re-
garding the presentation of mucormycosis such as sites of
involvement and infecting Mucorales species was not
captured in the Premiere Database. Finally, the costs of
mucormycosis-related hospitalizations varied significantly,
which could be due to the different underlying conditions
associated with the mucormycosis-related hospitalizations
[27]. Further studies identifying the additional cost attribut-
able solely to mucormycosis are needed to provide more
accurate estimates of the burden of mucormycosis.
Conclusions
The low prevalence of mucormycosis, its high clinical
and economic burden, and the fact that commonly used
antifungal therapies such as fluconazole and voricona-
zole are not effective against mucormycosis, indicate a
need to increase the awareness of mucormycosis among
physicians who routinely treat patients at high risk
mucormycosis for the infection, and the necessity of
active surveillance and optimized prophylactic treatment
in susceptible individuals.
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Additional files
Additional file 1: Figure S1. Sample Selection Flow Chart of
Mucormycosis-Related Hospitalizations. (TIF 707 kb)
Additional file 2: Table S1. Antifungal Drug Use. Presents the
prevalence of antifungal drug uses during the mucormycosis-related
hospitalizations with and without requiring use of amphotericin B or
posaconazole. (DOCX 29 kb)
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